AbbVie touts strong momentum for Skyrizi despite rising competition
If AbbVie executives are bothered by growing threats to their immunology powerhouse, they aren't letting on. Earlier this year, analysts were pondering how the company’s blockbuster Skyrizi might fare against competition from ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
